NCT07542028

Brief Summary

Renal transplantation is a major surgical procedure associated with significant postoperative pain, particularly due to lower abdominal incision, deep tissue dissection, and extensive surgical manipulation. Effective postoperative pain control is therefore of great importance in this patient population, as inadequate analgesia may impair early mobilization, delay recovery, increase opioid consumption, and contribute to opioid-related adverse effects. In addition, optimal analgesic management may improve patient comfort and support enhanced postoperative outcomes. Nerve blocks reduces opioid consumption in the postoperative period by providing better pain control and therefore has advantages such as fewer side effects and less risk of pulmonary and cardiac complications. In this study; it was aimed to compare the analgesic effectiveness of transversalis fascia plane block in the postoperative period in patients who underwent renal transplantation.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
18mo left

Started Apr 2026

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress2%
Apr 2026Oct 2027

First Submitted

Initial submission to the registry

April 14, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 21, 2026

Completed
6 days until next milestone

Study Start

First participant enrolled

April 27, 2026

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 4, 2027

Expected
14 days until next milestone

Study Completion

Last participant's last visit for all outcomes

October 18, 2027

Last Updated

April 28, 2026

Status Verified

April 1, 2026

Enrollment Period

1.4 years

First QC Date

April 14, 2026

Last Update Submit

April 27, 2026

Conditions

Keywords

Renal TransplantationTransversalis Fascia Plane Block

Outcome Measures

Primary Outcomes (1)

  • Pain Scores

    Pain will be assessed at rest and while coughing using the visual analog scale on a scale from 0 (no pain) to 10 (worst pain). Pain assessment will be done at 1st, 2nd, 4th, 12th, and 24th hours after surgery

    On the operation day

Secondary Outcomes (2)

  • Intraoperative opioid consumption

    Intraoperative period

  • Postoperative Opioid Consumption

    On the operation day

Study Arms (2)

Transversalis Fascia Plane Block Group

ACTIVE COMPARATOR

After the linear ultrasound (US) probe will be placed transversely above the iliac crest on the side of surgery, the abdominal wall muscle layers will be identified and the probe will be moved posteriorly until the transversus abdominis muscle and the transversalis fascia are visualized. A block needle will then be advanced using an in-plane technique, and after negative aspiration, 30 ml of 0.25% bupivacaine hydrochloride will be injected into the fascial plane between the transversus abdominis muscle and the transversalis fascia. Proper spread of the local anesthetic in this plane will be confirmed by ultrasound imaging. This procedure will be performed unilaterally on the surgical side. The standard intraoperative analgesic regimen will consist of intravenous tramadol (1 mg/kg) administered both before the incision and at the end of the procedure, with intravenous paracetamol (10 mg/kg) given exclusively at the end of the surgery.

Procedure: Transversalis Fascia Plane Block Group

Control Group

ACTIVE COMPARATOR

Participants in the control group will not receive any regional block intervention. The standard intraoperative analgesic regimen will consist of intravenous tramadol (1 mg/kg) administered both before the incision and at the end of the procedure, with intravenous paracetamol (10 mg/kg) given exclusively at the end of the surgery.

Procedure: Control Group

Interventions

This procedure will be performed unilaterally on the surgical side. 30 ml of 0.25% bupivacaine will be injected for ultrasound-guided transversalis fascia plane block application. The standard intraoperative analgesic regimen will consist of intravenous tramadol (1 mg/kg) administered both before the incision and at the end of the procedure, with intravenous paracetamol (10 mg/kg) given exclusively at the end of the surgery.

Transversalis Fascia Plane Block Group
Control GroupPROCEDURE

No peripheral nerve block will be performed. The standard intraoperative analgesic regimen will consist of intravenous tramadol (1 mg/kg) administered both before the incision and at the end of the procedure, with intravenous paracetamol (10 mg/kg) given exclusively at the end of the surgery.

Control Group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients aged 18-65 years
  • American Society of Anesthesiologists (ASA) score III
  • Body Mass Index (BMI) between 18-30 kg/m2

You may not qualify if:

  • Patients under 18 and over 65 years of age
  • Patients with an ASA score other than III
  • Patients with a history of bleeding diathesis
  • BMI below 18 or above 30 kg/m2

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Atakan Sezgi

Altındağ, Ankara, 06000, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Agnosia

Interventions

Control Groups

Condition Hierarchy (Ancestors)

Perceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Epidemiologic Research DesignEpidemiologic MethodsInvestigative TechniquesResearch DesignMethods

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 14, 2026

First Posted

April 21, 2026

Study Start

April 27, 2026

Primary Completion (Estimated)

October 4, 2027

Study Completion (Estimated)

October 18, 2027

Last Updated

April 28, 2026

Record last verified: 2026-04

Locations